USP22 and melanoma: To investigate the potential oncogenic mechanism of USP22, we initially generated USP22‐deficient melanoma cells via CRISPR–Cas9 technology (Figure 2A) and observed minimal suppression of cell proliferation, as detected by CCK‐8 assay (Figure S2A).